These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 15496167)

  • 1. Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy.
    Benigni A; Zoja C; Zatelli C; Corna D; Longaretti L; Rottoli D; Maggioni P; Todeschini M; Noris M; Remuzzi G
    Kidney Int; 2004 Nov; 66(5):1959-65. PubMed ID: 15496167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopeptidase inhibition normalizes blood pressure and restores endothelial function in renovascular hypertension.
    Quaschning T; Hocher B; Ruhl S; Kraemer-Guth A; Tilgner J; Wanner C; Galle J
    Kidney Blood Press Res; 2006; 29(6):351-9. PubMed ID: 17139187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans.
    Azizi M; Bissery A; Peyrard S; Guyene TT; Ozoux ML; Floch A; Ménard J
    Clin Pharmacol Ther; 2006 Jan; 79(1):49-61. PubMed ID: 16413241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining lisinopril and l-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis.
    Zoja C; Benigni A; Camozzi D; Corna D; Longaretti L; Todeschini M; Remuzzi G
    Kidney Int; 2003 Sep; 64(3):857-63. PubMed ID: 12911535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.
    Perico N; Zoja C; Corna D; Rottoli D; Gaspari F; Haskell L; Remuzzi G
    Kidney Int; 2009 Nov; 76(9):960-7. PubMed ID: 19625993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopeptidase inhibition prevents target organ damage and improves survival in spontaneously hypertensive rats.
    Linz W; Schäfer S; Afkham F; Gerl M; Schmidts HL; Rütten H
    J Renin Angiotensin Aldosterone Syst; 2006 Sep; 7(3):155-61. PubMed ID: 17094052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats.
    Wang JL; Cheng HF; Shappell S; Harris RC
    Kidney Int; 2000 Jun; 57(6):2334-42. PubMed ID: 10844603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
    Kostova E; Jovanoska E; Zafirov D; Jakovski K; Maleska V; Slaninka-Miceska M
    Bratisl Lek Listy; 2005; 106(12):407-11. PubMed ID: 16642666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasopeptidase inhibition attenuates proteinuria and podocyte injury in Zucker diabetic fatty rats.
    Fredersdorf S; Weil J; Ulucan C; Birner C; Büttner R; Schubert T; Böger CA; Debl K; Muders F; Riegger GA; Luchner A
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Apr; 375(2):95-103. PubMed ID: 17333128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.
    Daull P; Benrezzak O; Arsenault D; Pheng LH; Blouin A; Cayer J; Beaudoin M; Belleville K; Sirois P; Nantel F; Jeng AY; Battistini B
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1606-13. PubMed ID: 16364833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal damage after myocardial infarction is prevented by renin-angiotensin-aldosterone-system intervention.
    Windt WA; Eijkelkamp WB; Henning RH; Kluppel AC; de Graeff PA; Hillege HL; Schäfer S; de Zeeuw D; van Dokkum RP
    J Am Soc Nephrol; 2006 Nov; 17(11):3059-66. PubMed ID: 17005935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of SA7060, a novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, on deoxycorticosterone acetate-salt-induced hypertension in rats.
    Kuro T; Okahara A; Nose M; Ikuse T; Matsumura Y
    Biol Pharm Bull; 2000 Jul; 23(7):820-5. PubMed ID: 10919359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats.
    Cao Z; Burrell LM; Tikkanen I; Bonnet F; Cooper ME; Gilbert RE
    Kidney Int; 2001 Aug; 60(2):715-21. PubMed ID: 11473654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure.
    Ziai F; Ots M; Provoost AP; Troy JL; Rennke HG; Brenner BM; Mackenzie HS
    Kidney Int Suppl; 1996 Dec; 57():S132-6. PubMed ID: 8941934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats.
    Gardiner SM; Kemp PA; Brunner-Ferber F; Bennett T
    Br J Pharmacol; 1997 Dec; 122(8):1687-93. PubMed ID: 9422815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688.
    Gross O; Koepke ML; Beirowski B; Schulze-Lohoff E; Segerer S; Weber M
    Kidney Int; 2005 Aug; 68(2):456-63. PubMed ID: 16014022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II receptor blockade improves renal function in rats with reduced renal mass.
    Pollock DM; Divish BJ; Polakowski JS; Opgenorth TJ
    J Pharmacol Exp Ther; 1993 Nov; 267(2):657-63. PubMed ID: 8246138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelial-derived vasoactive mediators in polycystic kidney disease.
    Al-Nimri MA; Komers R; Oyama TT; Subramanya AR; Lindsley JN; Anderson S
    Kidney Int; 2003 May; 63(5):1776-84. PubMed ID: 12675853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure.
    Cohen DS; Mathis JE; Dotson RA; Graybill SR; Wosu NJ
    J Cardiovasc Pharmacol; 1998 Jul; 32(1):87-95. PubMed ID: 9676726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent.
    Schäfer S; Schmidts HL; Bleich M; Busch AE; Linz W
    Br J Pharmacol; 2004 Sep; 143(1):27-32. PubMed ID: 15289289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.